These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 11401008)

  • 1. Distinct temporal pattern of the effects of the combined serotonin-reuptake inhibitor and 5-HT1A agonist EMD 68843 on the sleep EEG in healthy men.
    Murck H; Frieboes RM; Antonijevic IA; Steiger A
    Psychopharmacology (Berl); 2001 May; 155(2):187-92. PubMed ID: 11401008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Behavioral and neurochemical effects of 5-(4-[4-(5-Cyano-3-indolyl)-butyl)-butyl]-1-piperazinyl)-benzofuran-2-carboxamide (EMD 68843): a combined selective inhibitor of serotonin reuptake and 5-hydroxytryptamine(1A) receptor partial agonist.
    Page ME; Cryan JF; Sullivan A; Dalvi A; Saucy B; Manning DR; Lucki I
    J Pharmacol Exp Ther; 2002 Sep; 302(3):1220-7. PubMed ID: 12183683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EMD 68843, a serotonin reuptake inhibitor with selective presynaptic 5-HT1A receptor agonistic properties.
    Bartoszyk GD; Hegenbart R; Ziegler H
    Eur J Pharmacol; 1997 Mar; 322(2-3):147-53. PubMed ID: 9098681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vilazodone: a 5-HT1A receptor agonist/serotonin transporter inhibitor for the treatment of affective disorders.
    Dawson LA; Watson JM
    CNS Neurosci Ther; 2009; 15(2):107-17. PubMed ID: 19499624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanism of action of the SPARI vilazodone: serotonin 1A partial agonist and reuptake inhibitor.
    Stahl SM
    CNS Spectr; 2014 Apr; 19(2):105-9. PubMed ID: 24673885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurochemical evaluation of the novel 5-HT1A receptor partial agonist/serotonin reuptake inhibitor, vilazodone.
    Hughes ZA; Starr KR; Langmead CJ; Hill M; Bartoszyk GD; Hagan JJ; Middlemiss DN; Dawson LA
    Eur J Pharmacol; 2005 Mar; 510(1-2):49-57. PubMed ID: 15740724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism of action of the bimodal antidepressant vilazodone: evidence for serotonin1A-receptor-mediated auto-augmentation of extracellular serotonin output.
    van Amsterdam C; Seyfried CA
    Psychopharmacology (Berl); 2014 Jun; 231(12):2547-58. PubMed ID: 24419272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Electrophysiological evidence for rapid 5-HT₁A autoreceptor inhibition by vilazodone, a 5-HT₁A receptor partial agonist and 5-HT reuptake inhibitor.
    Ashby CR; Kehne JH; Bartoszyk GD; Renda MJ; Athanasiou M; Pierz KA; Seyfried CA
    Eur J Pharmacol; 2013 Aug; 714(1-3):359-65. PubMed ID: 23872377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic EMD 68843 injections reduce anxiety in the shock-probe, but not the plus-maze test.
    Treit D; Degroot A; kashluba S; Bartoszyk GD
    Eur J Pharmacol; 2001 Mar; 414(2-3):245-8. PubMed ID: 11239925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vilazodone lacks proarrhythmogenic potential in healthy participants: a thorough ECG study.
    Edwards J; Sperry V; Adams MH; Gallipoli S; Thorn MD; Longstreth J; Boinpally R
    Int J Clin Pharmacol Ther; 2013 Jun; 51(6):456-65. PubMed ID: 23611569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of systemic injections of vilazodone, a selective serotonin reuptake inhibitor and serotonin 1A receptor agonist, on anxiety induced by predator stress in rats.
    Adamec R; Bartoszyk GD; Burton P
    Eur J Pharmacol; 2004 Nov; 504(1-2):65-77. PubMed ID: 15507223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug evaluation: Vilazodone--a combined SSRI and 5-HT1A partial agonist for the treatment of depression.
    de Paulis T
    IDrugs; 2007 Mar; 10(3):193-201. PubMed ID: 17351874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual 5-HT1A agonists and 5-HT re-uptake inhibitors by combination of indole-butyl-amine and chromenonyl-piperazine structural elements in a single molecular entity.
    Heinrich T; Böttcher H; Schiemann K; Hölzemann G; Schwarz M; Bartoszyk GD; van Amsterdam C; Greiner HE; Seyfried CA
    Bioorg Med Chem; 2004 Sep; 12(18):4843-52. PubMed ID: 15336263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vilazodone hydrochloride, a combined SSRI and 5-HT1A receptor agonist for major depressive disorder.
    Guay DR
    Consult Pharm; 2012 Dec; 27(12):857-67. PubMed ID: 23229074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of vilazodone in major depressive disorder: a randomized, double-blind, placebo-controlled trial.
    Croft HA; Pomara N; Gommoll C; Chen D; Nunez R; Mathews M
    J Clin Psychiatry; 2014 Nov; 75(11):e1291-8. PubMed ID: 25470094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vilazodone: in major depressive disorder.
    Frampton JE
    CNS Drugs; 2011 Jul; 25(7):615-27. PubMed ID: 21699273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vilazodone (Viibryd)--a new antidepressant.
    Med Lett Drugs Ther; 2011 Jul; 53(1368):53-4. PubMed ID: 21738107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The 5-HT1A agonist ipsapirone enhances EEG slow wave activity in human sleep and produces a power spectrum similar to 5-HT2 blockade.
    Seifritz E; Moore P; Trachsel L; Bhatti T; Stahl SM; Gillin JC
    Neurosci Lett; 1996 May; 209(1):41-4. PubMed ID: 8734905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vilazodone for the treatment of major depressive disorder.
    Iranikhah M; Wensel TM; Thomason AR
    Pharmacotherapy; 2012 Oct; 32(10):958-65. PubMed ID: 23033234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vilazodone: a novel antidepressant.
    Choi E; Zmarlicka M; Ehret MJ
    Am J Health Syst Pharm; 2012 Sep; 69(18):1551-7. PubMed ID: 22935937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.